A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/00 (2006.01) A61K 38/16 (2006.01) A61K 38/48 (2006.01) C07K 14/31 (2006.01)
Patent
CA 2447118
A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease conditions including stroke, myocardial infarction, sickle-cell crisis and venous thrombosis, is provided by the administration of a fibrinogen-binding protein capable of binding at the N-terminal B.beta. chain of fibrinogen, such as SdrG or Fbe, or their respective binding regions such as the A domain. In addition, compositions comprising effective amounts of the fibrinogen-binding proteins are also provided. The present anti-coagulation compositions have been shown to inhibit thrombin-induced fibrin clot formation by interfering with the release of fibrinopeptide B and the resulting anti-coagulation effects can be achieved without potential for causing or exacerbating unwanted side effects such as thrombocytopenia associated with prior art anticoagulants such as heparin.
L'invention concerne une méthode permettant de traiter et de prévenir de manière sûre et efficace les caillots de sang potentiellement dangereux, ou d'inhiber la coagulation du sang lorsqu'un tel effet est souhaitable, ce qui est le cas dans un large éventail de pathologies telles que les accidents vasculaires cérébraux, les infarctus du myocarde, les crises de la drépanocytose, et les thromboses veineuses. Ce procédé consiste à administrer une protéine liant le fibrinogène, capable de se lier à la chaîne B.beta. N-terminale de fibrinogène telle que SdrG ou Fbe, ou à leurs régions de liaison respectives telles que le domaine A. L'invention concerne en outre des compositions comprenant des doses actives de ces protéines de liaison de fibrinogène. On a montré que ces compositions anticoagulantes inhibent la formation du caillot de fibrine activée par la thrombine en interférant avec la libération du fibrinopeptide B, et permettent de produire des effets anticoagulants sans risque de provoquer ou d'exacerber des effets secondaires indésirables comme par exemple la thrombocytopénie associée aux anticoagulants connus à ce jour tels que l'héparine.
Davis Stacey
Hook Magnus A. O.
Shapiro Cohen
The Texas A. & M. University System
LandOfFree
Method and compositions for inhibiting thrombin-induced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for inhibiting thrombin-induced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for inhibiting thrombin-induced... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1817996